MOTIF

Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery

Coordinatore	KING'S COLLEGE LONDON    more  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: 442078000000 Fax: 442078000000
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	7˙612˙908 €
EC contributo	5˙818˙937 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-10-01   -   2016-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KING'S COLLEGE LONDON  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: 442078000000 Fax: 442078000000	UK (LONDON)	coordinator	1˙534˙670.50
2	Particle Sciences Inc.  Organization address address: Courtney Street 3894 city: Bethlehem postcode: 18017 contact info Titolo: Dr. Nome: Bruce Cognome: Frank Email: send email Telefono: 16108614701	US (Bethlehem)	participant	1˙005˙999.75
3	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES  Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 contact info Titolo: Mr. Nome: Olivier Cognome: Leroy Email: send email Telefono: +33 1 46 54 97 89 Fax: +33 1 46 54 91 80	FR (PARIS 15)	participant	713˙193.00
4	UNIVERSITA' DEGLI STUDI DI SIENA  Organization address address: VIA BANCHI DI SOTTO 55 city: SIENA postcode: 53100 contact info Titolo: Mrs. Nome: Sandra Cognome: Maggi Email: send email Telefono: +39 0577 233261	IT (SIENA)	participant	632˙760.00
5	THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN  Organization address address: KING'S COLLEGE REGENT WALK city: ABERDEEN postcode: AB24 3FX contact info Titolo: Mrs. Nome: Kerry Cognome: Kidd Email: send email Telefono: +44 1224 272663 Fax: +44 1224 272319	UK (ABERDEEN)	participant	578˙000.00
6	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: 442076000000	UK (LONDON)	participant	577˙406.00
7	MICROBIOTEC srl  Organization address address: Via delle Vigne 12 city: Monteriggioni (SI) postcode: 53035 contact info Titolo: Dr. Nome: Caterina Cognome: Cambiaggi Email: send email Telefono: +39 0577 318369	IT (Monteriggioni (SI))	participant	370˙080.00
8	MEDITOX S.R.O  Organization address address: POD ZAMKEM 279 city: KONAROVICE postcode: 28125 contact info Titolo: Dr. Nome: Martin Cognome: Slais Email: send email Telefono: +420 313 129 374 Fax: +420 131 129 366	CZ (KONAROVICE)	participant	250˙827.75
9	MINERVA CONSULTING & COMMUNICATION  Organization address address: Av. de Tervuren 32-34 city: BRUSSELS postcode: 1040 contact info Titolo: Mrs. Nome: Hinano Cognome: Spreafico Email: send email Telefono: 3225441888	BE (BRUSSELS)	participant	156˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The 40% protection against HIV-1 infection with vaginally-applied tenofovir gel demonstrated in the CAPRISA004 trial, has emphasized development of anti-retroviral (ARV)-based microbicides. Combining ARVs in a single product may provide increased protection. Development of a generally applicable formulation platform for combining ARVs (even if chemically incompatible) and understanding of the processes (drug uptake, efflux and metabolism) that determine tissue levels of microbicide are two important gaps in knowledge necessary for microbicide development. We propose to identify drug uptake and efflux transporters in cervicovaginal tissue and to use this information together with data on drug transporters from colorectal tissue to develop improved in vitro cell-based systems for biopharmaceutical screening. We also propose to develop a standardized drug encapsulation and formulation system that will allow insertion of any drug combinations. Informed by data on drug uptake, efflux and metabolism, these formulations will be further modified either by beneficial drug-drug interactions or by including selective inhibitors or inducers of drug transporters to optimize drug concentrations at target tissue sites. Comparative studies of drug transporters will also be performed in two important animal models, namely non-human primates (virus challenge ) and rabbit (regulatory toxicology). Optimised drug formulations will be tested in vitro and will undergo pharmacokinetic and pharmacodynamics studies in the animal models. Project outcomes will include a detailed description of drug transport in colorectal and cervicovaginal tissue to provide a rational basis for microbicide formulation, platform technology for formulating microbicide combinations optimized for vaginal or rectal delivery and prototype microbicide products for phase I clinical trial. The proposal should impact significantly on development of improved microbicides to prevent HIV infection.'

Introduzione (Teaser)

Antiretroviral drugs (ARVs) are the hope in the fight against HIV infection. Optimising the formulation and delivery mode of these microbicides could further improve treatment outcome.